Oculis (OCS) Stock Price, News & Analysis

Company Overview

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Key Stats

• Today's Range: $18.36 to $18.78
• 50-Day Range: $17.56 to $22.91
• 52-Week Range: $10.55 to $23.08
• Volume: 72,194 shs
• Average Volume: 45,265 shs
• Market Capitalization: $760.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.50
• Consensus Rating: Buy

Oculis Stock Analysis - MarketRank™

Oculis scored higher than 46% of companies evaluated by MarketBeat, and ranked 634th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Oculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oculis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oculis are expected to grow in the coming year, from ($2.09) to ($2.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oculis is -9.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oculis is -9.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oculis has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Oculis has been sold short.

Short Interest Ratio / Days to Cover

Oculis has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oculis has recently decreased by 14.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oculis does not currently pay a dividend.

Dividend Growth

Oculis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.08% of the float of Oculis has been sold short.

Short Interest Ratio / Days to Cover

Oculis has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oculis has recently decreased by 14.09%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.04

News Sentiment

Oculis has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Oculis this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oculis insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 22.30% of the stock of Oculis is held by institutions.

OCS Stock Analysis - Frequently Asked Questions

How have OCS shares performed this year?

Oculis' stock was trading at $17.00 at the start of the year. Since then, OCS stock has increased by 10.3% and is now trading at $18.7450.
View the best growth stocks for 2025 here.

How were Oculis' earnings last quarter?

Oculis Holding AG (NASDAQ:OCS) issued its quarterly earnings data on Tuesday, March, 11th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.28. Oculis had a negative net margin of 8,043.28% and a negative trailing twelve-month return on equity of 71.31%.

Who are Oculis' major shareholders?

Oculis' top institutional shareholders include abrdn plc (2.49%), Bank of America Corp DE (0.07%), Citadel Advisors LLC (0.06%) and Geode Capital Management LLC (0.04%).

How do I buy shares of Oculis?

Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oculis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oculis investors own include SoFi Technologies (SOFI), Meta Platforms (META), Bitdeer Technologies Group (BTDR), Purpose Bitcoin ETF (BTCC.B), Booz Allen Hamilton (BAH), Broadcom (AVGO) and Atara Biotherapeutics (ATRA).

Company Calendar

• Last Earnings: 3/11/2025
• Today: 3/14/2025
• Next Earnings (Estimated): 3/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OCS
• CIK: 1953530
• Web: www.oculis.com
• Phone: 41-21-711-3970
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $29.50
• High Stock Price Target: $41.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +57.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-98,920,000.00
• Net Margins: -8,043.28%
• Pretax Margin: N/A
• Return on Equity: -71.31%
• Return on Assets: -56.85%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 4.02
• Quick Ratio: 4.02

Sales & Book Value

• Annual Sales: $980,000.00
• Price / Sales: 774.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.87 per share
• Price / Book: 6.53

Miscellaneous

• Outstanding Shares: 40,504,000
• Free Float: N/A
• Market Cap: $759.04 million
• Optionable: Not Optionable
• Beta: 0.02